InNexus Biotechnology Appoints Chief Scientific Officer.BRITISH COLUMBIA, Canada -- InNexus Biotechnology Inc. (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension Venture: IXS (Integrated XSeries Server) An x86-based xSeries server (motherboard and memory) from IBM that plugs into an iSeries or i5 midrange computer. Running Windows or Linux, the IXS shares disk storage, server management, user administration with its iSeries/i5 host. , OTCBB OTCBB See OTC Bulletin Board (OTCBB). : IXSBF), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking technology has appointed Dr. Heinz Kohler, Chief Scientific Officer. Dr. Kohler pioneered the development of Dynamic Cross Linking technology and has been with InNexus since its inception. Dr. Kohler holds both a MD and Ph.D. and has long-standing experience in the development of antibodies, documented in over 200 peer-reviewed publications. He is listed as Inventor on numerous patents, including the primary patents for InNexus' Dynamic Cross Linking technology. He was instrumental in the start-up of numerous companies including IDEC IDEC Instituto Brasileiro de Defesa do Consumidor (Portugese: Brazilian Consumer Protection Agency) IDEC Information Design & End-User Computing IDEC Interior Design Educators Council, Inc. Pharmaceuticals, as Director of Research. Prior to his appointment, he served as InNexus' VP of Research and has been a Professor at the University of Chicago, the University of SUNY SUNY - State University of New York at Buffalo and the University of California The University of California has a combined student body of more than 191,000 students, over 1,340,000 living alumni, and a combined systemwide and campus endowment of just over $7.3 billion (8th largest in the United States). San Diego, and Director of Molecular Immunology at the Roswell Park Cancer Center. InNexus President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Jeff Morhet said, "We are all very excited to have the inventor and developer of Dynamic Cross Linking technology leading our company's scientific efforts." Dr. Kohler replaces Charles Morgan in the role of CSO (Chief Security Officer) The person in charge of all staff members who are responsible for promulgating, enforcing and administering security policies for all systems within an enterprise or division. , who will be taking a less active role in the Company in order to pursue other interests. In conjunction with stepping down from the role of CSO, Morgan has also resigned as a Director of the Company, but will continue in the role of special consultant and scientific advisor to the Company. InNexus wishes to acknowledge Morgan's years of service and contributions to the Company as a director, officer and early shareholder and looks forward to his continued support and contributions. About InNexus InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking technology (DXL[TM]) improving the potency of existing antibody products while opening new markets and disease applications. DXL[TM] antibodies utilize unique, novel and patented methods and technologies of InNexus. InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of The Mayo Clinic and has its own in-house developmental facilities. These development facilities provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.innexusbiotech.com. The TSX Venture Exchange TSX Venture Exchange Originally called the Canadian Venture Exchange (CDNX), this was a result of the merger of the Vancouver and Alberta stock exchanges. The goal of TSX Venture Exchange is to provide venture companies with effective access to capital while protecting investors. has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements regarding future events. Such forward-looking statements involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control that may cause actual results or performance to differ materially from those currently anticipated in such statements. On behalf of the Board of Directors of InNexus Biotechnology, Inc. "Jeff Morhet" Jeff Morhet, President, CEO & Chairman The TSX Venture Exchange has neither approved nor disapproved of the information contained herein. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion